Literature DB >> 16033503

Institutional variability in a minimal risk, population-based study: recognizing policy barriers to health services research.

Craig D Newgard1, Sai-Hung Joshua Hui, Patrick Stamps-White, Roger J Lewis.   

Abstract

OBJECTIVE: To describe (1) the institutional variability in study approval and willingness to obtain federal assurance documents for a federally supported, minimal risk health services research project conducted during the implementation of the Privacy Rule and federalwide assurances, and (2) the potential impact of such policy on selection of research subjects and generalizability of study results. DATA SOURCES: Primary data collection from 2001 to 2004. STUDY
DESIGN: We provide a descriptive analysis of a prospective, observational, out-of-hospital study. STUDY
SETTING: Twenty-seven pediatric receiving hospitals were approached for participation in a study validating a decision rule to identify seriously injured children involved in motor vehicle crashes in Los Angeles County. Two federal research policies, the Privacy Rule and the requirement for federalwide assurances, were implemented during the project. DATA COLLECTION: All 27 hospitals were sent an identical research protocol requesting approval to review charts of children transported to their facility. The research protocol included strict confidentiality protections, was noninterventional, did not alter the standard of care at the scene or at the hospital, and met requirements for waivers of both informed consent and the Health Insurance Portability and Accountability Act. Because the project was federally supported, all participating hospitals were required to have a federalwide assurance. The hospitals receiving the research protocol were the unit of analysis and outcomes included: approval of the research protocol, total number of days to study approval, and successfully obtaining a federalwide assurance. PRINCIPLE
FINDINGS: Overall, 6 of 27 (22 percent) hospitals refused to participate in the study, all of which were community hospitals. The median time from submitting an application to study approval was 118 days (interquartile range 34-254, range 12-960 days) and time to study approval differed when hospitals were categorized by type and the presence of an institutional review board (p=.053). No institutional review resulted in a change in the basic study protocol, although one hospital required paramedic consent. Following intensive efforts to secure federalwide assurances, 12 of 27 hospitals (44 percent) possessed the necessary assurance to conduct the study. If all patients transported to hospitals that failed to obtain such an assurance were omitted, the sample size would have been reduced by 62 percent and would have excluded all children transported to community hospitals.
CONCLUSIONS: There is substantial institutional variability in approval of a minimal risk observational study and in willingness to obtain a federalwide assurance, particularly among community hospitals. Federal research policy involving patient privacy and institutional assurances may be contributing to this variability, which can adversely affect selection of research subjects, disrupt population-based study design, and threaten the generalizability of study results.

Entities:  

Mesh:

Year:  2005        PMID: 16033503      PMCID: PMC1361194          DOI: 10.1111/j.1475-6773.2005.00408.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  16 in total

1.  IRBs search for answers and support during a time of institutional change.

Authors:  D F Phillips
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

2.  Institutional review boards: a crisis in confidence.

Authors:  R J Levine
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

3.  A central institutional review board for multi-institutional trials.

Authors:  Michaele C Christian; Jacquelyn L Goldberg; Jack Killen; Jeffrey S Abrams; Mary S McCabe; Joan K Mauer; Robert E Wittes
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

4.  Improving protection for research subjects.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

5.  Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.

Authors:  T O Stair; C R Reed; M S Radeos; G Koski; C A Camargo
Journal:  Acad Emerg Med       Date:  2001-06       Impact factor: 3.451

6.  Variations in institutional review board decisions for HIV quality of care studies: a potential source of study bias.

Authors:  C L Bennett; A M Sipler; J P Parada; M B Goetz; J A DeHovitz; R A Weinstein
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-01       Impact factor: 3.731

7.  Variability among institutional review boards' decisions within the context of a multicenter trial.

Authors:  H Silverman; S C Hull; J Sugarman
Journal:  Crit Care Med       Date:  2001-02       Impact factor: 7.598

8.  Breaking the camel's back: multicenter clinical trials and local institutional review boards.

Authors:  W J Burman; R R Reves; D L Cohn; R T Schooley
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

9.  Use of out-of-hospital variables to predict severity of injury in pediatric patients involved in motor vehicle crashes.

Authors:  Craig D Newgard; Roger J Lewis; B Tilman Jolly
Journal:  Ann Emerg Med       Date:  2002-05       Impact factor: 5.721

10.  Updating protections for human subjects involved in research. Project on Informed Consent, Human Research Ethics Group.

Authors:  J Moreno; A L Caplan; P R Wolpe
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

View more
  7 in total

1.  Ethics review as a component of institutional approval for a multicentre continuous quality improvement project: the investigator's perspective.

Authors:  Hanna Ezzat; Sue Ross; Peter von Dadelszen; Tara Morris; Robert Liston; Laura A Magee
Journal:  BMC Health Serv Res       Date:  2010-07-30       Impact factor: 2.655

2.  Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial.

Authors:  Brian T Helfand; Anne K Mongiu; Claus G Roehrborn; Robert F Donnell; Reginald Bruskewitz; Steven A Kaplan; John W Kusek; Laura Coombs; Kevin T McVary
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

3.  The Resuscitation Outcomes Consortium Epistry-Trauma: design, development, and implementation of a North American epidemiologic prehospital trauma registry.

Authors:  Craig D Newgard; Gena K Sears; Thomas D Rea; Daniel P Davis; Ronald G Pirrallo; Clifton W Callaway; Dianne L Atkins; Ian G Stiell; Jim Christenson; Joseph P Minei; Carolyn R Williams; Laurie J Morrison
Journal:  Resuscitation       Date:  2008-05-15       Impact factor: 5.262

4.  The Myth of Community Differences as the Cause of Variations Among IRBs.

Authors:  Robert Klitzman
Journal:  AJOB Prim Res       Date:  2011

5.  Differences and structural weaknesses of institutional mechanisms for health research ethics: Burkina Faso, Palestine, Peru, and Democratic Republic of the Congo.

Authors:  N'koué Emmanuel Sambiéni
Journal:  BMC Med Ethics       Date:  2018-06-15       Impact factor: 2.652

6.  Partnering with healthcare facilities to understand psychosocial distress screening practices among cancer survivors: pilot study implications for study design, recruitment, and data collection.

Authors:  Diane Ng; M Shayne Gallaway; Grace C Huang; Theresa Famolaro; Jennifer Boehm; Karen Stachon; Elizabeth A Rohan
Journal:  BMC Health Serv Res       Date:  2021-03-17       Impact factor: 2.655

7.  The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication.

Authors:  Kirk D Midkiff; Elizabeth B Andrews; Alicia W Gilsenan; Dennis M Deapen; David H Harris; Maria J Schymura; Francis J Hornicek
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-04-19       Impact factor: 2.890

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.